<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">kurskvest</journal-id><journal-title-group><journal-title xml:lang="ru">Человек и его здоровье</journal-title><trans-title-group xml:lang="en"><trans-title>Humans and their health</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1998-5746</issn><issn pub-type="epub">1998-5754</issn><publisher><publisher-name>Kursk State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21626/vestnik/2022-3/09</article-id><article-id custom-type="elpub" pub-id-type="custom">kurskvest-1070</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАЦЕВТИЧЕСКИЕ НАУКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACEUTICAL SCIENCES</subject></subj-group></article-categories><title-group><article-title>Разработка методики определения содержания остаточных органических растворителей в новой фармацевтической субстанции кислоты 3-(1H-бензимидазол-2-ил)-1,2,2-триметилциклопентан-карбоновой</article-title><trans-title-group xml:lang="en"><trans-title>Development of methods for determining the content of residual organic solvents in a new pharmaceutical substance of 3-(1H-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane-carboxylic acid</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3614-0569</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Метелев</surname><given-names>Антон Васильевич</given-names></name><name name-style="western" xml:lang="en"><surname>Metelev</surname><given-names>Anton V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>химик-аналитик лаборатории контроля качества, ООО «БЕЛФАРМАМЕД», г. Белгород</p></bio><bio xml:lang="en"><p>chemical analyst of the quality control laboratory, LLC “BELFARMAMED”, Belgorod, Russian Federation</p></bio><email xlink:type="simple">chemic2022@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6970-2444</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Казакова</surname><given-names>Валентина Сергеевна</given-names></name><name name-style="western" xml:lang="en"><surname>Kazakova</surname><given-names>Valentina S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. фарм. наук, начальник отдела контроля качества, ООО «БЕЛФАРМАМЕД», г. Белгород; доцент кафедры фармацевтической технологии, НИУ «БелГУ», г. Белгород</p></bio><bio xml:lang="en"><p>Cand. Sci. (Pharm.), Head of the quality control department, LLC “BELFARMAMED”, Belgorod, Russian Federation; Associate Professor at the Department of Pharmaceutical Technology, BNRU, Belgorod, Russian Federation</p></bio><email xlink:type="simple">kazakova@bsu.edu.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5539-1390</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фадеева</surname><given-names>Дарья Александровна</given-names></name><name name-style="western" xml:lang="en"><surname>Fadeeva</surname><given-names>Dariya A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. фарм. наук, доцент кафедры фармацевтической технологии, НИУ «БелГУ», г. Белгород</p></bio><bio xml:lang="en"><p>Cand. Sci. (Pharm.), Associate Professor at the Department of Pharmaceutical Technology, BNRU, Belgorod, Russian Federation</p></bio><email xlink:type="simple">fadeeva@bsu.edu.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8897-0076</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бузов</surname><given-names>Андрей Анатольевич</given-names></name><name name-style="western" xml:lang="en"><surname>Buzov</surname><given-names>Andrey A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. тех. наук, зам. директора, ООО «БЕЛФАРМАМЕД», г. Белгород</p></bio><bio xml:lang="en"><p>Cand. Sci. (Tech.), Deputy Director, LLC “BELFARMAMED”, Belgorod, Russian Federation</p></bio><email xlink:type="simple">buzov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1033-0789</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чуев</surname><given-names>Владимир Петрович</given-names></name><name name-style="western" xml:lang="en"><surname>Chuev</surname><given-names>Vladimir P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р. тех. наук, ген. директор, АО «ОЭЗ»ВладМиВа», г. Белгород</p></bio><bio xml:lang="en"><p>Dr. Sci. (Tech.), General Director, JSC “VLADMIVA” EXPERIMENTAL PLANT, Belgorod, Russian Federation</p></bio><email xlink:type="simple">chuev@vladmiva.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ООО «БЕЛФАРМАМЕД»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>LLC “BELPHARMAMED”</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ООО «БЕЛФАРМАМЕД»; Белгородский государственный национальный исследовательский университет (НИУ БелГУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>LLC “BELPHARMAMED”; Belgorod national research university (BNRU)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Белгородский государственный национальный исследовательский университет (НИУ БелГУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Belgorod national research university (BNRU)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>АО «Опытно-экспериментальный завод «ВладМиВа» (АО «ОЭЗ»ВладМиВа»)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>JSC “VLADMIVA” Experimental plant</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>27</day><month>10</month><year>2022</year></pub-date><volume>25</volume><issue>3</issue><fpage>81</fpage><lpage>92</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Метелев А.В., Казакова В.С., Фадеева Д.А., Бузов А.А., Чуев В.П., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Метелев А.В., Казакова В.С., Фадеева Д.А., Бузов А.А., Чуев В.П.</copyright-holder><copyright-holder xml:lang="en">Metelev A.V., Kazakova V.S., Fadeeva D.A., Buzov A.A., Chuev V.P.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.kursk-vestnik.ru/jour/article/view/1070">https://www.kursk-vestnik.ru/jour/article/view/1070</self-uri><abstract><p>Органические растворители, зачастую обладающие токсическими и/или канцерогенными свойствами, применяют на всех этапах производства фармацевтических субстанций - синтезе, выделении и очистке - и полностью не удаляются после завершения технологического процесса. Наличие даже крайне малых количеств таких соединений в лекарственных средствах может представлять опасность для пациентов. В статье изложены результаты разработки методики определения содержания остаточных органических растворителей (ООР) - спирта этилового, толуола и диметилформамида - в новой активной фармацевтической субстанции (АФС) - кислоте 3-(1H-бензимидазол-2-ил)-1,2,2-триметилциклопентан-карбоновой методом газовой хроматографии. Материалы и методы. Для идентификации и количественного определения ООР использован статический парофазный анализ. Определение остаточных органических растворителей проводили методом внутреннего стандарта с использованием газового хроматографа Shimadzu GC-2014ATF/SPL с автосамплером AOC-6000Plus, была использована хроматографическая колонка Restek SH-Rtx-624MS, 0.32 мм, 30 м, 1,8 мкм, детекция - пламенно-ионизационная. В качестве внутреннего стандарта использован спирт изобутиловый. Результаты. Разработанная методика использована для определения содержания остаточных органических растворителей в валидационных сериях новой фармацевтической субстанции кислоты 3-(1H-бензимидазол-2-ил)-1,2,2-триметилциклопентан-карбоновой. Проведена валидация методики в соответствии с требованиями Государственной Фармакопеи РФ. Заключение. Разработанная методика пригодна для дальнейшего использования в контроле качества при производстве кислоты 3-(1H-бензимидазол-2-ил)-1,2,2-триметилциклопентан-карбоновой.</p></abstract><trans-abstract xml:lang="en"><p>Objective. Organic solvents, which often have toxic and/or carcinogenic properties, are used at all stages of the production of pharmaceutical substances - synthesis, isolation and purification - and are not completely removed after the completion of the technological process. The presence of even extremely small amounts of such compounds in medicines can be dangerous for patients. The article presents the results of the development of a method for determining the content of residual organic solvents (ROS) - ethanol, toluene and dimethylformamide - in a new active pharmaceutical ingredient (API) 3-(1H-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane-carboxylic acid by gas chromatography. Materials and methods. Static vapor phase analysis was used to identify and to quantify residual organic solvents. It was determined by the internal standard method using a Shimadzu GC-2014ATF/SPL gas chromatograph with an AOC-6000Plus autosampler; PID detection. Isobutyl alcohol was used as an internal standard. Results. The developed method was used to determine the content of residual organic solvents in the validation series of the new pharmaceutical substance 3-(1H-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane-carboxylic acid. The method was validated in accordance with the requirements of the State Pharmacopoeia of the Russian Federation. Conclusion. The developed method is suitable for further use in quality control in the production of 3-(1H-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane-carboxylic acid.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>активная фармацевтическая субстанция (АФС)</kwd><kwd>остаточные органические растворители (ООР)</kwd><kwd>кислота 3-(1H-бензимидазол-2-ил)-1</kwd><kwd>2</kwd><kwd>2-триметилциклопентан-карбоновая</kwd><kwd>контроль качества</kwd><kwd>идентификация</kwd><kwd>количественное определение</kwd></kwd-group><kwd-group xml:lang="en"><kwd>active pharmaceutical substance (API)</kwd><kwd>residual solvents (RS)</kwd><kwd>3-(1h-benzimidazol-2-yl)-1</kwd><kwd>2</kwd><kwd>2-trimethyl cyclopentancarbonic acid</kwd><kwd>quality control</kwd><kwd>identification</kwd><kwd>assay</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Покровский М.В., Чуев В.П., Бузов А.А., Коваленко С.Н., Кравченко А.В., авторы; ООО «БЕЛФАРМАМЕД», патентообладатель. 3-(1Н-бензимидазол-2-ил)-1,2,2-триметилциклопентан-карбоновая кислота, обладающая кардиопротекторной активностью. Российская Федерация патент RU 2645356. 21 февраля 2018 г. EDN: ZEDDHV</mixed-citation><mixed-citation xml:lang="en">Pokrovskij M. V., Chuev V.P., Buzov A.A., Kovalenko S.N., Kravchen-ko A.V, authors; LLC "BELFARMAMED", assignee. 3-(1H-benzimidazol-2-yl)-1,2,2-trimethyl cyclopentancarbonic acid with cardioprotective activity.Russian Federation patent RU 2645356. 2018 Feb 21 (in Russ.). EDN: ZEDDHV</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Чуев В.П., Бузов А.А., Коваленко С.Н., Мерзликин С.И., Штрыголь С.Ю., авторы; ООО «ВладМиВа», патентообладатель. Фармацевтическая антидиабетическая композиция на основе (+)-цис-3-(1Н-бензимидазол-2-ил)-1,2,2-триметилциклопентан-карбоновой кислоты. Российская Федерация патент RU 2624872. 07 июля 2017 г. EDN: WWFWNX</mixed-citation><mixed-citation xml:lang="en">Chuev V.P., Buzov A.A., Kovalenko S.N., Merzlikin C.I., Strygol C.Y., authors; LLC "VladMiVa", assignee. Pharmaceutical antidiabetic composition based on (+)-cis-3-(1H-benzimidazol-2-yl)-1,2,2-trimethylcyclopentane carboxylic acid.Russian Federation patent RU 2624872. 2017 Jul 21 (in Russ.). EDN: WWFWNX</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Метелев А.В., Казакова В.С., Фадеева Д.А., Бузов А.А., Чуев В.П. Разработка методик для установления норм качества новой фармацевтической субстанции кислоты 3-(1H-бензимидазол-2-ил)-1,2,2-триметилциклопентан-карбоновой. Медицина. 2022;10(1):19-31. DOI: 10.29234/2308-9113-2022-10-1-19-31. EDN: AIATDX</mixed-citation><mixed-citation xml:lang="en">Metelev A.V., Kazakova V.S., Fadeeva D.A., Buzov A.A., Chuev V.P. Elaboration of techniques for quality control of a new active pharmaceutical substance of 3-(1h-benzimidazol-2-yl)-1,2,2-trimethyl cyclopentancarbonic acid. Medicine. 2022;10(1):19-31 (in Russ.). DOI: 10.29234/2308-9113-2022-10-1-19-31. EDN: AIATDX</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Reid G.L. Residual solvents. In: Specification of Drug Substances and Products. Elsevier, 2020:345-365. DOI: 10.1016/B978-0-08-102824-7.00013-0</mixed-citation><mixed-citation xml:lang="en">Reid G.L. Residual solvents. In: Specification of Drug Substances and Products. Elsevier, 2020:345-365. DOI: 10.1016/B978-0-08-102824-7.00013-0</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sattineni S.R., Joseph A., Das S., Chaitainya B., Rao S. Method development and validation for the determination of residual solvents in racecadotril by gas chromatography. Current Pharmaceutical Analysis. 2021;17(9):1232-1239. DOI: 10.2174/1573412916999200819163552</mixed-citation><mixed-citation xml:lang="en">Sattineni S.R., Joseph A., Das S., Chaitainya B., Rao S. Method development and validation for the determination of residual solvents in racecadotril by gas chromatography. Current Pharmaceutical Analysis. 2021;17(9):1232-1239. DOI: 10.2174/1573412916999200819163552</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bawazeer S. Development and validation of chromatographic methods for the quantitative determination of toltrazuril and its residual solvents. Hail Journal of Health Sciences. 2020;2(1):9-18. DOI: 10.4103/1658-8312.347570</mixed-citation><mixed-citation xml:lang="en">Bawazeer S. Development and validation of chromatographic methods for the quantitative determination of toltrazuril and its residual solvents. Hail Journal of Health Sciences. 2020;2(1):9-18. DOI: 10.4103/1658-8312.347570</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Chawla R.K., Koteswara Rao G.S.N., Kulandaivelu U., Panda S.P., Alavala R.R. Development and validation of a headspace gas chromatographic (HS-GC) method for determination of residual solvents in nitazoxanide API.Int J Res Pharm Sci. 2020;11(SPL4):1719-1727. DOI: 10.26452/ijrps.v11iSPL4.4362</mixed-citation><mixed-citation xml:lang="en">Chawla R.K., Koteswara Rao G.S.N., Kulandaivelu U., Panda S.P., Alavala R.R. Development and validation of a headspace gas chromatographic (HS-GC) method for determination of residual solvents in nitazoxanide API.Int J Res Pharm Sci. 2020;11(SPL4):1719-1727. DOI: 10.26452/ijrps.v11iSPL4.4362</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Noorbasha K., Shaik A. Determination of residual solvents in paclitaxel by headspace gas chromatography. Futur J Pharm Sci. 2021;7(1):1-17. DOI: 10.1186/s43094-021-00186-7</mixed-citation><mixed-citation xml:lang="en">Noorbasha K., Shaik A. Determination of residual solvents in paclitaxel by headspace gas chromatography. Futur J Pharm Sci. 2021;7(1):1-17. DOI: 10.1186/s43094-021-00186-7</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Rao S.S., Vijayalakshmi A. Analytical method development and validation of glipizide to determine residual solvents by head space-gas chromatography. Research Journal of Pharmacy and Technology. 2021;14(5):2440-2444. DOI: 10.52711/0974-360X.2021.00429</mixed-citation><mixed-citation xml:lang="en">Rao S.S., Vijayalakshmi A. Analytical method development and validation of glipizide to determine residual solvents by head space-gas chromatography. Research Journal of Pharmacy and Technology. 2021;14(5):2440-2444. DOI: 10.52711/0974-360X.2021.00429</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Louati K., Mouna S., Fathi S. Development and Validation of a Separation and Quantification Method for Residual Solvents in Active Substances by Headspace Gas Chromatography. American Academic Scientific Research Journal for Engineering, Technology, and Sciences. 2018;41(1):57-75</mixed-citation><mixed-citation xml:lang="en">Louati K., Mouna S., Fathi S. Development and Validation of a Separation and Quantification Method for Residual Solvents in Active Substances by Headspace Gas Chromatography. American Academic Scientific Research Journal for Engineering, Technology, and Sciences. 2018;41(1):57-75</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
